US drug discovery firm's Q2 operating revenue fell and missed analyst expectations
Q2 net loss narrowed yr/yr but was higher than analyst estimates
Analyst coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Recursion Pharmaceuticals, Inc. is $6.00, about 81.3% above its August 4 closing price of $3.31
Outlook and program updates
Company lowers 2026 cash operating expense guidance to under $375 mln from under $390 mln
Recursion expects its cash runway to extend into early 2028 under current plans
Phase 1/2 trial for REC-7735 expected to start in 2H26; REC-4881 registrational path update expected 2H26
Result drivers and key details
Collaboration revenue drop - Q2 revenue declined due to less revenue recognized from Roche and Genentech collaboration as certain project phases were completed in the prior period
- Research and development expenses decreased, mainly due to lower platform costs and improved operating efficiency
RXRX•
